AR122127A1 - VACUNA DE b-AMILOIDE PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER - Google Patents
VACUNA DE b-AMILOIDE PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMERInfo
- Publication number
- AR122127A1 AR122127A1 ARP210101370A ARP210101370A AR122127A1 AR 122127 A1 AR122127 A1 AR 122127A1 AR P210101370 A ARP210101370 A AR P210101370A AR P210101370 A ARP210101370 A AR P210101370A AR 122127 A1 AR122127 A1 AR 122127A1
- Authority
- AR
- Argentina
- Prior art keywords
- amyloid
- disease
- alzheimer
- peptide
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063079806P | 2020-09-17 | 2020-09-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122127A1 true AR122127A1 (es) | 2022-08-17 |
Family
ID=80776325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101370A AR122127A1 (es) | 2020-09-17 | 2021-05-19 | VACUNA DE b-AMILOIDE PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230364210A1 (https=) |
| EP (1) | EP4213942A4 (https=) |
| JP (1) | JP2023541669A (https=) |
| KR (1) | KR20230087495A (https=) |
| CN (1) | CN116724046A (https=) |
| AR (1) | AR122127A1 (https=) |
| AU (1) | AU2021345451A1 (https=) |
| CA (1) | CA3192383A1 (https=) |
| IL (1) | IL301223A (https=) |
| MX (1) | MX2023003009A (https=) |
| TW (1) | TW202212348A (https=) |
| WO (1) | WO2022060424A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| USRE50630E1 (en) | 2017-10-31 | 2025-10-14 | Creative BioPeptides, Inc. | Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| US11510961B2 (en) | 2019-12-19 | 2022-11-29 | Creative Bio-Peptides, Inc. | Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| EP4661891A2 (en) * | 2023-02-06 | 2025-12-17 | Creative Bio-Peptides Inc. | Peptides for treating neurological disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840838A (en) * | 1996-02-29 | 1998-11-24 | University Of Kentucky Research Foundation | Process for enhancing the activity of amyloid β peptides |
| US8173127B2 (en) * | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
| AT506819B1 (de) * | 2008-06-12 | 2011-06-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzin zur behandlung von alzheimer-krankheit |
| GB201113570D0 (en) * | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
| US12304935B2 (en) * | 2016-07-29 | 2025-05-20 | Juno Therapeutics, Inc. | Immunomodulatory polypeptides and related compositions and methods |
| BR112022023366A2 (pt) * | 2020-05-19 | 2023-05-02 | Othair Prothena Ltd | Vacina com múltiplos epítopos para o tratamento de mal de alzheimer |
-
2021
- 2021-05-19 US US18/245,523 patent/US20230364210A1/en active Pending
- 2021-05-19 TW TW110118154A patent/TW202212348A/zh unknown
- 2021-05-19 AR ARP210101370A patent/AR122127A1/es unknown
- 2021-05-19 CA CA3192383A patent/CA3192383A1/en active Pending
- 2021-05-19 JP JP2023517697A patent/JP2023541669A/ja active Pending
- 2021-05-19 AU AU2021345451A patent/AU2021345451A1/en active Pending
- 2021-05-19 EP EP21869919.7A patent/EP4213942A4/en active Pending
- 2021-05-19 CN CN202180063988.4A patent/CN116724046A/zh active Pending
- 2021-05-19 MX MX2023003009A patent/MX2023003009A/es unknown
- 2021-05-19 WO PCT/US2021/033180 patent/WO2022060424A1/en not_active Ceased
- 2021-05-19 IL IL301223A patent/IL301223A/en unknown
- 2021-05-19 KR KR1020237012808A patent/KR20230087495A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021345451A1 (en) | 2023-04-13 |
| US20230364210A1 (en) | 2023-11-16 |
| IL301223A (en) | 2023-05-01 |
| EP4213942A4 (en) | 2025-01-08 |
| TW202212348A (zh) | 2022-04-01 |
| MX2023003009A (es) | 2023-04-10 |
| EP4213942A1 (en) | 2023-07-26 |
| JP2023541669A (ja) | 2023-10-03 |
| WO2022060424A1 (en) | 2022-03-24 |
| KR20230087495A (ko) | 2023-06-16 |
| CN116724046A (zh) | 2023-09-08 |
| CA3192383A1 (en) | 2022-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR122127A1 (es) | VACUNA DE b-AMILOIDE PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER | |
| CL2022003253A1 (es) | Vacuna multiepítopo para el tratamiento de la enfermedad de alzheimer | |
| MX2023001503A (es) | Vacuna de multiples epitopos para tratamiento de la enfermedad de alzheimer. | |
| CO2022004902A2 (es) | Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer | |
| MX2020009856A (es) | Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp). | |
| MX384227B (es) | Anticuerpos y fragmentos de unión a antígenos para usarse en el tratamiento y la profilaxis de amiloidosis. | |
| MX2021009622A (es) | Metodos para tratar la colestasis. | |
| MX2023003008A (es) | Vacuna de multiples epitopos para el tratamiento de la enfermedad de alzheimer. | |
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| AR122129A1 (es) | Vacuna de tau para el tratamiento de la enfermedad de alzheimer | |
| MX2020001732A (es) | Tratamiento de las afecciones del sistema nervioso central. | |
| NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
| UY27721A1 (es) | Anticuerpos humanizados que reconocen el peptido amiloide beta. | |
| MX2015017307A (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington. | |
| EA201490277A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| CL2021003312A1 (es) | Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma. | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| AR093182A1 (es) | Metodo para tratar el sobrepeso o la obesidad | |
| AR107893A1 (es) | TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE | |
| AR114392A1 (es) | Tratamiento de pacientes con enfermedad de fabry clásica | |
| CO2022005113A2 (es) | Métodos de tratamiento para modificar la hemodinámica | |
| MX383462B (es) | Pridopidina para el tratamiento de las discinesias inducidas por fármacos | |
| EA200970127A1 (ru) | Модулятор рецепторов глюкокортикостероидов и способы его применения | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. |